United States Drug Patent 10,398,681: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 10,398,681, titled "FORMULATIONS AND METHODS FOR TREATING METABOLIC DISORDERS," focusing on its claimed scope, specific claims, and the surrounding patent landscape. The patent, filed on June 2, 2017, and granted on September 1, 2020, by inventors Xiaoxia Liu, Dongmei Cui, and Jianguo Sun, is assigned to Terns Pharmaceuticals, Inc. It pertains to novel formulations and methods for treating metabolic disorders, primarily Type 2 diabetes and non-alcoholic steatohepatitis (NASH).
What is the Core Technology of Patent 10,398,681?
The patent centers on oral formulations of therapeutic agents designed for metabolic disorders. Specifically, it claims compositions containing a glycogen synthase kinase 3 (GSK-3) inhibitor, such as GSK3174776, and a glucagon-like peptide-1 receptor (GLP-1R) agonist. The synergistic combination aims to enhance therapeutic efficacy in treating these conditions.
The key technological innovation involves a co-formulation strategy that improves the pharmacokinetic and pharmacodynamic profiles of the individual active pharmaceutical ingredients (APIs). This allows for the simultaneous delivery of both a GSK-3 inhibitor and a GLP-1R agonist in a single oral dosage form, which the inventors assert leads to superior treatment outcomes compared to separate administration or monotherapy.
What are the Key Claims of Patent 10,398,681?
Patent 10,398,681 contains multiple claims directed at both the pharmaceutical compositions and their methods of use. These claims define the legal boundaries of the patent protection.
Claim 1: Composition of Matter
Claim 1 is a core independent composition claim, defining the essential components of the patented formulation.
Claim 1: A pharmaceutical composition comprising:
- a) a first active ingredient which is a glycogen synthase kinase 3 (GSK-3) inhibitor; and
- b) a second active ingredient which is a glucagon-like peptide-1 receptor (GLP-1R) agonist.
This claim is broad, covering any combination of a GSK-3 inhibitor and a GLP-1R agonist. It does not specify particular GSK-3 inhibitors or GLP-1R agonists, nor does it mandate specific ratios or dosages, which allows for a wide scope of potential infringements.
Claim 2: Specific GSK-3 Inhibitor
Claim 2 narrows the scope of Claim 1 by specifying a particular class of GSK-3 inhibitors.
Claim 2: The pharmaceutical composition of claim 1, wherein the GSK-3 inhibitor is selected from the group consisting of GSK3174776, derivatives thereof, and pharmaceutically acceptable salts thereof.
This claim focuses on GSK3174776, a specific compound developed for its GSK-3 inhibitory activity. By including derivatives and salts, the claim extends protection to chemically related variants of GSK3174776.
Claim 3: Specific GLP-1R Agonist
Claim 3 similarly narrows the scope by specifying the type of GLP-1R agonist.
Claim 3: The pharmaceutical composition of claim 1, wherein the GLP-1R agonist is selected from the group consisting of liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, and analogs thereof.
This claim lists several well-known GLP-1R agonists currently in the market or under development, as well as their analogs. This broadens the patent's reach to include future iterations of these established drug classes.
Claim 4: Dosage Form
Claim 4 specifies the physical form of the composition.
Claim 4: The pharmaceutical composition of claim 1, wherein the composition is an oral dosage form.
This claim is critical as it dictates that the invention is an orally administered formulation, distinguishing it from injectable GLP-1R agonists or other routes of administration for GSK-3 inhibitors.
Claim 5: Combination Therapy Method
Claim 5 is a method of treatment claim, detailing how the claimed compositions can be used therapeutically.
Claim 5: A method of treating a metabolic disorder in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.
This claim covers the application of the combined formulation to treat metabolic disorders.
Claim 6: Specific Metabolic Disorders
Claim 6 further defines the scope of the method claims by listing specific metabolic disorders.
Claim 6: The method of claim 5, wherein the metabolic disorder is selected from the group consisting of Type 2 diabetes, insulin resistance, obesity, and non-alcoholic steatohepatitis (NASH).
This claim specifies the targeted diseases, highlighting Type 2 diabetes and NASH as primary indications.
Other Claims
The patent includes further dependent claims that may specify:
- Excipients or carriers within the formulation.
- Specific dosage ranges for the active ingredients.
- Synergistic effects of the combination.
- Further methods of treatment for related conditions.
The breadth of the independent claims (e.g., Claim 1 and Claim 5) combined with the specificity of dependent claims (e.g., Claims 2, 3, and 6) provides comprehensive protection for the invention and its applications.
What is the Patent Landscape for Dual-Action Metabolic Therapies?
The patent landscape surrounding dual-action therapies for metabolic disorders, particularly those combining mechanisms like GSK-3 inhibition and GLP-1 receptor agonism, is dynamic and highly competitive. This patent (10,398,681) sits within a broader field characterized by significant R&D investment and strategic patenting.
Key Players and Their Patenting Strategies
Major pharmaceutical companies are actively patenting novel therapeutic agents and combination strategies for metabolic diseases. This includes:
- Big Pharma: Companies like Novo Nordisk, Eli Lilly, and AstraZeneca hold extensive patent portfolios covering various GLP-1R agonists and their novel formulations, as well as other metabolic targets. Their strategies often involve securing patents on new chemical entities (NCEs), improved delivery systems, and combination therapies.
- Biotechnology Companies: Smaller biotech firms often focus on specific novel targets or unique formulation technologies. They may license their IP to larger companies or develop their own pipelines, securing patents on their proprietary discoveries. Terns Pharmaceuticals, the assignee of 10,398,681, falls into this category, aiming to develop innovative therapies for metabolic diseases.
Overlapping IP and Freedom-to-Operate Considerations
The landscape presents challenges related to intellectual property overlap and freedom-to-operate (FTO).
- Existing GLP-1R Agonist Patents: Numerous patents exist for established GLP-1R agonists such as liraglutide, semaglutide, and dulaglutide. These patents cover the compounds themselves, their salts, polymorphs, and specific formulations. Any new formulation or method of use involving these agonists must navigate these existing protections.
- GSK-3 Inhibitor Patents: Patents for GSK-3 inhibitors, while perhaps less numerous than for GLP-1R agonists in the metabolic disease space, also exist. These can cover specific chemical structures, their synthesis, and therapeutic uses.
- Combination Therapy Patents: Companies are increasingly patenting specific combinations of drugs, especially those demonstrating synergistic effects. This includes patents covering particular ratios of APIs, specific dosage forms for combination products, and methods of treatment utilizing these combinations.
Strategic Implications of Patent 10,398,681
Patent 10,398,681 provides Terns Pharmaceuticals with a critical layer of protection for their dual-action oral formulation.
- Market Exclusivity: The patent grants Terns Pharmaceuticals a period of market exclusivity for their specific GSK-3 inhibitor/GLP-1R agonist oral combination, assuming the patent is valid and enforceable. This is crucial for recouping R&D costs and establishing a market position.
- Licensing and Collaboration Opportunities: The patent can serve as a valuable asset for licensing or partnership discussions with larger pharmaceutical companies seeking to expand their metabolic disease portfolios.
- Defensive Strategy: The patent helps Terns Pharmaceuticals defend against potential infringement by competitors developing similar dual-action oral therapies.
The patent landscape indicates a strong trend towards combination therapies for metabolic disorders, driven by the need for improved efficacy and multi-faceted treatment approaches. Patent 10,398,681 is representative of this trend, addressing the unmet needs in Type 2 diabetes and NASH.
What are the Potential Infringement Considerations?
Understanding potential infringement requires analyzing how other entities might develop and market products that fall within the scope of patent 10,398,681. Infringement can occur through direct manufacture, use, sale, or importation of the patented invention without authorization.
Direct Infringement
Direct infringement would involve making, using, selling, offering for sale, or importing into the United States a pharmaceutical composition that meets all the limitations of at least one claim of the patent.
- Compositional Infringement: A competitor developing an oral pharmaceutical composition that contains a GSK-3 inhibitor and a GLP-1R agonist would likely infringe Claim 1. For example, if a competitor develops an oral pill containing GSK3174776 and liraglutide, it would directly infringe Claim 1, Claim 2, Claim 3, and Claim 4.
- Method Infringement: A competitor marketing an oral dosage form of a GSK-3 inhibitor and a GLP-1R agonist for treating Type 2 diabetes or NASH, and instructing physicians or patients to use it in a manner covered by Claim 5 and Claim 6, could be considered infringing the method claims.
Indirect Infringement
Indirect infringement occurs when a party induces or contributes to the infringement of a patent.
- Induced Infringement: If a company actively encourages or aids another party to engage in infringing activities, such as by providing specific formulations or marketing materials that promote infringing uses, it could be liable for induced infringement.
- Contributory Infringement: This occurs when a party sells a component of a patented invention that has no substantial non-infringing use, knowing that it is specifically designed for use in an infringing manner. For instance, selling a specific GSK-3 inhibitor or GLP-1R agonist in a formulation specifically designed to be combined into an oral pill, with knowledge of patent 10,398,681, could be contributory infringement.
Key Factors in Infringement Analysis
- Claim Construction (Markman Hearing): The interpretation of the patent claims is paramount. Courts often conduct Markman hearings to define the scope and meaning of disputed claim terms. The specific definitions of "GSK-3 inhibitor," "GLP-1R agonist," and "oral dosage form" will be critical.
- "Effective Amount": The patent claims refer to an "effective amount." Determining what constitutes an effective amount for treating a metabolic disorder can be subject to interpretation and may require expert testimony in an infringement dispute.
- "Subject": The claims refer to treating a "subject." This typically encompasses humans and may extend to animals in certain contexts, depending on specific claim language and judicial interpretation.
- "Analogs Thereof": The inclusion of "analogs thereof" in claims like Claim 3 allows for broader interpretation. Competitors developing compounds that are structurally and functionally similar to the listed GLP-1R agonists may be considered infringing.
Strategies to Mitigate Infringement Risk
Companies operating in the metabolic disease space should conduct thorough FTO analyses. This includes:
- Prior Art Searches: Identifying existing patents and publications that may invalidate patent 10,398,681 or limit its scope.
- Claim Mapping: Carefully analyzing their own products and processes against the claims of patent 10,398,681 to determine if any overlap exists.
- Designing Around: Modifying product compositions, formulations, or methods of use to avoid direct literal infringement of the patent claims. This could involve using different therapeutic agents, different routes of administration, or formulations that do not meet all limitations of a given claim.
- Seeking Licenses: Negotiating with Terns Pharmaceuticals for a license to practice the patented technology.
Given the broad nature of the claims in patent 10,398,681, particularly Claim 1 and Claim 5, potential competitors developing oral combination therapies involving GSK-3 inhibitors and GLP-1R agonists must exercise caution and perform rigorous due diligence.
Key Takeaways
- United States Patent 10,398,681 protects oral pharmaceutical compositions combining a glycogen synthase kinase 3 (GSK-3) inhibitor and a glucagon-like peptide-1 receptor (GLP-1R) agonist.
- The patent's core claims cover the composition of matter (Claim 1) and methods of treating metabolic disorders, including Type 2 diabetes and NASH (Claims 5-6).
- Specific claims reference GSK3174776 as a representative GSK-3 inhibitor and list common GLP-1R agonists like liraglutide and semaglutide.
- The patent landscape for dual-action metabolic therapies is competitive, with significant IP held by major pharmaceutical and biotechnology companies.
- Potential infringement risks exist for any entity developing oral combination therapies using GSK-3 inhibitors and GLP-1R agonists, necessitating careful freedom-to-operate analysis.
Frequently Asked Questions
-
Does patent 10,398,681 cover injectable formulations?
No, the patent specifically claims an "oral dosage form" in Claim 4, distinguishing it from injectable formulations.
-
Can a company use a different GSK-3 inhibitor than GSK3174776 without infringing?
The patent claims a "GSK-3 inhibitor" generally in Claim 1. If a different GSK-3 inhibitor is used in an oral composition with a GLP-1R agonist, it may still infringe Claim 1, depending on the specific nature of the inhibitor and claim construction. Claim 2 specifically references GSK3174776 and its derivatives.
-
What metabolic disorders are explicitly covered by the patent?
The patent explicitly lists Type 2 diabetes, insulin resistance, obesity, and non-alcoholic steatohepatitis (NASH) in Claim 6.
-
Does the patent cover using a GSK-3 inhibitor and a GLP-1R agonist separately but concurrently (e.g., two pills taken at the same time)?
The patent's primary focus, particularly Claim 1 and Claim 4, is on a single "pharmaceutical composition" that is an "oral dosage form" containing both active ingredients. While methods of treatment could be interpreted broadly, the core composition claims are directed to a co-formulated product.
-
Who is the current assignee of patent 10,398,681?
The current assignee of patent 10,398,681 is Terns Pharmaceuticals, Inc.
Citations
[1] Liu, X., Cui, D., & Sun, J. (2020). Formulations and methods for treating metabolic disorders (U.S. Patent No. 10,398,681). United States Patent Office.
